NCT05320146View on ClinicalTrials.gov

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

March 4, 2022

Primary Completion Date

July 18, 2023

Study Completion Date

July 18, 2023

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
OTHER

MRI-PDFF

Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.

Trial Locations (9)

77079

305, Houston

78229

Site 212, San Antonio

78539

Site 213, Edinburg

78757

Site 211, Austin

85224

Site 207, Chandler

85712

Site 209, Tucson

91402

Site 214, Panorama City

92704

Site 233, Santa Ana

98105

226, Seattle

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY